CN103127358B - Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method - Google Patents
Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method Download PDFInfo
- Publication number
- CN103127358B CN103127358B CN201310066048.8A CN201310066048A CN103127358B CN 103127358 B CN103127358 B CN 103127358B CN 201310066048 A CN201310066048 A CN 201310066048A CN 103127358 B CN103127358 B CN 103127358B
- Authority
- CN
- China
- Prior art keywords
- weight portion
- hours
- chinese medicine
- medicine composition
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention relates to a traditional Chinese medicine composition for treating rheumatoid arthritis and a preparation method, which comprises the following raw materials by weight: 10-20 parts of radix clematidis, 10-30 parts of Rhizoma Dioscoreae Nipponicae and 10-15 parts of pawpaw. The preparation method comprises the following steps: extracting radix clematidis, Rhizoma Dioscoreae Nipponicae and pawpaw.mixture by water and depositing, performing vacuum concentration to obtain the thick paste state, then adding conventional auxiliary materials to prepare the powders, tablets, granules, hard capsules and pills. The traditional Chinese medicine composition for treating rheumatoid arthritis has obvious effects on wind cold dampness and collaterals impassability due to morning stiffness of joints, pain, inflexible extension and pain in back and loin caused by rheumatoid arthritis.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition and preparation method thereof, particularly a kind of Chinese medicine composition for the treatment of rheumatoid arthritis and preparation method thereof, belong to field of traditional Chinese medicine pharmacy.
Background technology
The autoimmune disease that rheumatoid arthritis (rheumatoid arthritis, RA) is is main manifestations with synovium of joint chronic inflammatory disease.At home and abroad still belong to agnogenic " disease of refractory " at present.According to statistics, whole world prevalence average 1.0% is 0.32 ~ 0.36% in population of China prevalence, and it causes crowd disability and one of principal disease disabled.RA patient bears huge misery and torment, and external habit is referred to as " 5D ", that is: painful (discomfort), maimed (disability), economic loss (dollar loss), drug side effect (drug reactions), dead (death).Its severe patient can occur that dysfunction is even disabled, causes serious burden to society and family.American professor Pincus emphasizes that a lot of aspect of RA is similar with hypertension to diabetes, as being all chronic disease, will not long-term control vitals at a specified future date all can be caused to damage.Therefore, good, that toxic and side effects the is few medicine of exploitation clinical efficacy is the problem that doctor and patient wish eagerly jointly, Unfortunately there is no the ideal medicament to treatment RA at present.Though the different classes of chemosynthesis antirheumatic of external exploitation have certain curative effect because of side effect can not life-time service, also the state of an illness can only be improved by the nonsteroidal anti-inflammatory (NSAID) that rheumatism association of the U.S. is recommended, RA can not be cured, and because of side effects of pharmaceutical drugs can not prolonged application in clinical, disease enters late period or deformity and then needs to replace artificial joint." B&J 10 yearly plan " calls medicine of state of an illness effect less side effect " development and application change " that World Health Organization (WHO) proposes, west lays particular emphasis on the research of biological preparation for the cause of disease, and existing rheumatism biological preparation appearance.The research of China is still in the starting stage, clinical chemical drugs used mostly is introduced variety, there is no the intellectual property of oneself, although there is advantageous resources of medicinal plant in China, the Traditional Chinese Medicine Anti medicine for rheumatism developed with this is no doubt many, but because of complicated component, mechanism is failed to understand, be difficult to approve by the world, even the Radix Tripterygii Wilfordii of most study (as blue sterling T2) can only be called as " alternative medicine " medicine so far in west.Therefore, make full use of China's resources of medicinal plant, exploitation Traditional Chinese Medicine Anti RA preparation, has positive clinical meaning.
Summary of the invention
The object of the invention is to provide a kind of Chinese medicine composition for the treatment of rheumatoid arthritis and preparation method thereof.
The present invention seeks to be achieved through the following technical solutions.
The crude drug of Chinese medicine composition of the present invention consists of:
Radix Clematidis 10-20 weight portion, Rhizoma Dioscoreae Nipponicae 10-30 weight portion, Fructus Chaenomelis 10-15 weight portion.
The crude drug of Chinese medicine composition of the present invention preferably consists of:
Radix Clematidis 15 weight portion, Rhizoma Dioscoreae Nipponicae 20 weight portion, Fructus Chaenomelis 10 weight portion.
The crude drug of Chinese medicine composition of the present invention preferably consists of:
Radix Clematidis 12 weight portion, Rhizoma Dioscoreae Nipponicae 27 weight portion, Fructus Chaenomelis 11 weight portion.
The crude drug of Chinese medicine composition of the present invention preferably consists of:
Radix Clematidis 18 weight portion, Rhizoma Dioscoreae Nipponicae 13 weight portion, Fructus Chaenomelis 14 weight portion.
The crude drug of Chinese medicine composition of the present invention preferably consists of:
Radix Clematidis 17 weight portion, Rhizoma Dioscoreae Nipponicae 18 weight portion, Fructus Chaenomelis 12 weight portion.
Crude drug of the present invention is Chinese medicinal material, can commercially buy.
Get traditional Chinese medicinal composition raw materials of the present invention, add customary adjuvant, conveniently technique, makes powder, tablet, hard capsule, soft capsule, drop pill, pill, honeyed pill, granule, soft extract with bee honey agent, slow releasing preparation, controlled release preparation, quick releasing formulation, oral liquid or ejection preparation.
Pharmaceutical composition of the present invention can be prepared as follows:
Radix Clematidis, Rhizoma Dioscoreae Nipponicae, Fructus Chaenomelis adds 6 ~ 10 times amount soak by water 1 ~ 4 time, each decoction 1 ~ 2 hour, filter, filtrate and above-mentioned aqueous solution merge, being concentrated into 50 DEG C of heat survey relative densities is 1.28, stirring adds ethanol, make containing amount of alcohol to 60%, leave standstill 24 hours ~ 28 hours, get after supernatant reclaims ethanol and be evaporated to 50 DEG C of heat survey relative densities 1.30 again, add 3 ~ 5 times of water gagings stirrings and make precipitation, leave standstill 12 ~ 48 hours, get supernatant and be evaporated to thick paste, add customary adjuvant, conveniently technique, make powder, tablet, granule, hard capsule, pill.
Pharmaceutical composition of the present invention is preferably as follows method preparation:
Radix Clematidis, Rhizoma Dioscoreae Nipponicae, Fructus Chaenomelis adds 8 times of water gagings, decoct 3 times, each decocting time is followed successively by 1.5 hours, 1 hour, 1 hour, filter, filtrate and above-mentioned aqueous solution merge, being concentrated into 50 DEG C of heat survey relative densities is 1.28, stirring adds ethanol, make containing amount of alcohol to 60%, leave standstill 24 hours ~ 28 hours, get after supernatant reclaims ethanol and be evaporated to 50 DEG C of heat survey relative densities 1.30 again, add 4 times of water gagings stirrings and make precipitation, leave standstill 24 hours, get supernatant and be evaporated to thick paste, add customary adjuvant, conveniently technique, make powder, tablet, granule, hard capsule, pill.
Particularly, the preparation method of medicament composition granule agent of the present invention is as follows:
Radix Clematidis, Rhizoma Dioscoreae Nipponicae, Fructus Chaenomelis adds 8 times of water gagings, decoct 3 times, each decocting time is followed successively by 1.5 hours, 1 hour, 1 hour, filter, filtrate and above-mentioned aqueous solution merge, being concentrated into 50 DEG C of heat survey relative densities is 1.28, stirring adds ethanol, make containing amount of alcohol to 60%, leave standstill 24 hours ~ 28 hours, get after supernatant reclaims ethanol and be evaporated to 50 DEG C of heat survey relative densities 1.30 again, add 4 times of water gagings stirrings and make precipitation, leave standstill 24 hours, get supernatant and be evaporated to thick paste, consumption adds adjuvant maltodextrin routinely, stevioside, cold drying is pulverized, use 50% alcohol granulation, 60 ~ 80 DEG C of dryings, granulate, seal more than 12 hours, subpackage, obtain.
Chinese medicine composition of the present invention is the proved recipe collecting clinical experience for many years, is made up of Radix Clematidis, Rhizoma Dioscoreae Nipponicae, Fructus Chaenomelis three herbal medicine.The dry root and rhizome that monarch drug Radix Clematidis (Clematis chinensis Osbeck.) is Ranunculaceae Clematis Radix Clematidis, Xin Xian, temperature, enter 12 warps, expelling wind and removing dampness, removing obstruction in the collateral to relieve pain, pungent loose happiness is walked, tonneau warm in nature, can be passed through the twelve regular channels, stimulate the menstrual flow and reach network, for anemofrigid-damp arthralgia, articular instability, muscle is numb, and muscles and bones is ached.Ministerial drug Rhizoma Dioscoreae Nipponicae is the rhizome for Dioscoreaceae plant Dioscorea nipponica Mak. Ningpo Yam Rhizome (Dioscorea nipponica Makino.), bitter flat, enters Liver Channel, has soothing the channels and quicking the network vessels, the merit of promoting blood circulation and stopping pain, principal drug assistance removing obstruction in the collateral to relieve pain.Adjuvant drug Fructus Chaenomelis is the dry almost ripe fruit of rosaceous plant chaenomeles lagenaria Chaenomelesspeciosa (Sweet) Nakai, acid temperature, gas are fragrant, enter Liver Channel, damp eliminating relaxing muscles and tendons, helps ministerial drug muscles and tendons relaxing to alleviate pain, alleviates the anxious pain of muscle arteries and veins contraction, large for arthralgia chiefly caused by damp pathogen puffiness of the legs, soreness of waist and knee joint, arthroncus, clonic spasm of the muscle flaccidity of the lower limbs.Wetting and invade muscle, is then arthralgia chiefly caused by damp pathogen, the humidity hysteresis of the logical flesh natural fibre line of meat of the kind temperature of this product, therefore is the key medicine of the anxious pain of warm and humid numbness and grain contraction.The merit of the relaxing muscles and tendons that dispels the wind, removing obstruction in the collateral to relieve pain played altogether by three taste medicines, joint morning stiff distortion, pain, the joint stuffiness caused rheumatoid arthritis and lumbar and back pain belongs to wind-cold-damp retention, the obstructed person of channels acts on significantly.
Clinical trial shows that traditional Chinese medicine composition for treating rheumatoid arthritis of the present invention not only truly has curative effect improving in symptom, sign and experimental index, and finds no obvious toxic and side effects compared with matched group, refers to experimental example.
Following experimental example and embodiment are used for further illustrating but are not limited to the present invention.
Experimental example 1, Chinese medicinal composition granules of the present invention (being called as Radix Clematidis dragon granule in the present invention) Study on Preparation
Chinese medicine composition of the present invention is the proved recipe collecting clinical experience for many years, former side uses with decoction, this research is in view of decoction inconvenience in use, keeping on the basis that former prescription is constant, former side is developed into sugar free granule, thus make its drug effect reliable more rapidly, take and carry convenient, quality is more stable.
(1) preparation technology's mentality of designing
Radix Clematidis dragon granule prescription is made up of Radix Clematidis, Rhizoma Dioscoreae Nipponicae, Fructus Chaenomelis three taste Chinese medicine, its compound preparation composition is comparatively complicated, the modern composition of shortage system and pharmacological research data, therefore this research foundation Chinese medical theory is under the prerequisite keeping former decoction amount and clinical efficacy, in conjunction with modern interrelated data and Chinese medicine preparation feature, Radix Clematidis dragon granule is designed as follows: (1) adopts decoction and alcohol sedimentation technique to extract the Radix Clematidis in prescription, Rhizoma Dioscoreae Nipponicae, Fructus Chaenomelis respectively, extract merges, and cold drying is pulverized.(2) consider the indication of this preparation, need reduce, on the impact of stomach physiological environment and taking of diabetics, to be conducive to the dispersed quick absorption of medicine simultaneously, therefore to select sugar free granule type as far as possible.(3) for increasing the moisture resistance of granule, making granule not easily moisture absorption caking in storage, adding appropriate maltodextrin as moisture retardant.Add the mouthfeel that sweeting agent (stevioside) corrects granule discomfort.
(2) experimentation
For ensureing that the curative effect of novel formulation is equal to former dosage form, in prescription, three herbal medicines still adopt the extraction conditions of decoction, namely with water boiling and extraction.
Water lixivium: take Radix Clematidis, Rhizoma Dioscoreae Nipponicae, Fructus Chaenomelis three taste medical material by recipe quantity, mixed powder is broken into 10 order left and right coarse powder, take tap water as solvent, carry out according to " hot dipping " under Pharmacopoeia of the People's Republic of China version " algoscopy of extractum " (annex XA) item in 2010, result shows its leaching rate 15 ± 0.5%.
Extraction time and number of times: the character of decocting condition and the prescription Chinese medicine carried in conjunction with decoction, through repeatedly extracting test and scale up test, result shows: solvent dosage is 8 times, decocting and carrying number of times is 3 times, extraction time is followed successively by 1.5 hours, 1 hour, 1 hour, its relative extraction ratio is all more than 91.9%, therefore said extracted condition is as the better condition of water extraction.
(3) technique explanatory notes
Owing in preparation process being the melting of increase granule, carry out water extract-alcohol precipitation, the heat time heating time of preparing dry extract is longer, for preventing thermal sensitivity effective ingredient failure loss, heated time and the heating temperature of medicine should be controlled especially in the processes such as concentrate drying, therefore concentrated should adopt concentrating under reduced pressure method, drying should adopt vacuum dehydrating at lower temperature method.
The smashing fineness of dry extract should be basically identical with maltodextrin fineness, to ensure the uniformity mixed.According to the difference of drying means, drying and crushing after equivalent extract also can be selected to mix with appropriate maltodextrin; Sweeting agent selects stevioside, and consumption is 0.3% ~ 0.4%.With about 50% alcohol granulation, concentration too little then soft material viscosity is too large, is not easy to dry granulate of granulating, and concentration is too large, and then soft material viscosity is too little, made particle powder and granule more.
This prescribed dose three herbal medicine is 9000g altogether, 3600g granule should be obtained, actual preparation amount is 3600g ± 80g (variant between separate sources medical material) (subpackage 6g/ bag/600 pouch, every bag containing crude drug 15g), in preparation process, overall control should carry out increase and decrease adjustment according to dry extract quantity to dextrin consumption.
Experimental example 2, traditional Chinese medicine composition for treating rheumatoid arthritis of the present invention clinical research
One, data and method
1. diagnostic criteria
The diagnostic criteria that 1.1 diagnostic criteria Western medicine diagnose standards reference 1987 Americanism damp disease association (ARA) revise: 1. morning is stiff; 2. the arthritis of more than at least 3 joint parts; 3. the arthritis of joints of hand; 4. symmetry arthritis; 5. rheumatoid nodules; 6. rheumatoid factor positive; 7. radiology changes.4 persons in above-mentioned 7 are had to be diagnosed as rheumatoid arthritis.And conditions of patients is in active stage [arthroncus, pain are obvious, and erythrocyte sedimentation rate speeds, c reactive protein increases].TCM syndrome diagnostic criteria is worked out with reference to " guideline of clinical investigations of new Chinese medicine treatment rheumatoid arthritis ".
The improvement Disease Activity standard that 1.2RA severity extent judgment criteria adopts European rheumatism alliance (EULAR) to formulate, is called for short DAS28-3.DAS28-3=[0.56 × SQRT (tenderness number)+0.28 × SQRT (swelling number)+0.70 × LN (erythrocyte sedimentation rate)] × 1.08+0.16; Catabasis: DAS28-3 < 2.6; Low activeness: DAS28-3 < 3.2; Medium activity: 3.2 < DAS28-3≤5.1; High activeness: DAS28-3 > 5.1.
1. 1.3 inclusive criterias meet above-mentioned Diseases of WM diagnostic criteria and TCM syndrome diagnostic criteria, and activeness is medium or more, and arthritis progress is the RA patient of I, II, III phase.2. the age was at 18 ~ 65 years old.3. informed consent is obtained.
Though 1. 1.4 exclusion standards are primary disease, long-term taking Western medicine or other medicines person.2. late deformity, maimed person, disability person.3. the age is under-18s or over-65s person, trimester of pregnancy or women breast-feeding their children those who are allergic to this drug.4. the severe primary disease psychotics such as cardiovascular, liver, kidney and hemopoietic system are merged.5. do not meet inclusive criteria, not by regulation medication, the not congruent safety judgement person that affects the treatment of curative effect or data cannot be judged.
2. data
Outpatient service 80 example in 100 routine cases, 20 examples of being in hospital, are divided into test group 50 example at random according to table of random number, matched group 50 example.Wherein test group man 16 example, female 34 example; 25 ~ 60 years old age, average 40.60 ± 12.84; The course of disease 3 months ~ 30 years, average 3.60 ± 3.40 years.Matched group man 14 example, female 36 example; 23 ~ 58 years old age, average 41.52 ± 10.48, course of disease March ~ 31 year, average 3.28 ± 3.16 years.Difference (P > 0.05) that two groups of sexes, age, the course of disease compare that there are no significant, has comparability.
3. Therapeutic Method
Oral Radix Clematidis dragon granule (being prepared from by embodiment 1) of test group, specification: 6g/ bag, each 6g, every day 3 times; The oral ibuprofen of matched group (specification 0.3g/ sheet), each 0.3g, every day 2 times; Radix Tripterygii Wilfordii tablet (specification 12ug/ sheet), each 2, every day 3 times.
4. observation index
4.1 health giving quality indexs 1. clinical symptoms and sign, comprises joint stiff time in morning (with a minute note), the cold temperature of pain degree, swelling degree, swelling number, articular pain degree, local joint, the average grip of two hands (mmHg); 2. pain relieving onset time, detumescence onset time, pain relieving persistent period, walking 15 meters of time, range of motion; 3. lab testing: ESR, RF, ASO, affected joints x-ray check.
Cardinal symptom, sign scoring method 1. arthralgia degree: 0 point; Without pain: 1 point; Mild pain, does not affect sleep: 2 points; Moderate pain, pain generally seldom continues, but send out time angor, before the treatment two nights, every night at least show effect 1 time, impact sleep.2. articular pain degree; 0 point: without tenderness, weight or work amount large movable time without tenderness; 1 point: mild tenderness, at joint margins or touch ligament weight, patient claims there is tenderness; 2 points: moderate tenderness, though frown discomfort during weight, activity is slightly limited; 3 points: severe tenderness, during weight, patient retreats, passive activity critical constraints.3. range of motion: 0 point: activity freely; 1 point: gentle activity is limited; 2 points: activity is obviously limited; 3 points: completely stiff.4. Articular swelling: 0 point: pneumonedema; 1 point: mild swelling, neighbouring apophysis is clearly visible; 2 points: swelling is equal with apophysis; 3 points: swelling is equal with apophysis, affect functional activity.
4.2 safety indexes routine blood tests, routine urinalysis, liver function, renal function (creatinine) and adverse events thereof.
Before and after 4.3 observational techniques treatments, itemized record clinical symptoms and experiment each 1 time of Testing index.
5. curative effect determinate standard
Curative effect determinate standard is according to " new Chinese medicine guideline of clinical investigations ".Effective: affected joints swells and ache disappearance, and function of joint recovers normal substantially, and main physical and chemical index is normal.Effective: affected joints myalgia, swelling alleviates, and function of joint activity takes a turn for the better, and main physical and chemical index close to normal, or takes a favorable turn.Invalid: affected joints muscle symptoms is without improvement, and main physical and chemical index is without improvement.
Symptom efficacy assessment standard: effective: symptom integral value decline > 2/3 after treatment.Effective: after treatment, symptom integral value declines 2/3 ~ 1/3.Invalid: after treatment, symptom integral value is not as good as 1/3.
6. statistical method
Adopt SPSS11.5 statistical software, group data X
2inspection, measurement data t checks.
Two, result
1. a liang group total effects compares
Two groups of total effectses compare, and test group curative effect is better than matched group, specifically in table 1.
A table 1 liang group total effects compares
Note: compare P < 0.05 with matched group
2. liang group cardinal symptom sign comparitive study
Two groups of cardinal symptoms, sign treatment front and back self-contrasts have significant difference (P < 0.01).After treatment, improvement, the curative effect of 15 meters of walking times of test group arthralgia degree, swelling and morning stiff time are all better than matched group (P < 0.05).Two groups of articular pains, mobility, grips compare no difference of science of statistics (P > 0.05), specifically in table 2.
Symptom comparitive study before and after table 2 liang group treatment
Note: compare with after treatment of control group
Δp < 0.05,
△ △p < 0.01
3. liang group arthralgia relief onset time and detumescence onset time, pain relieving persistent period compare
Two groups of pain relieving onset times and detumescence onset time, the pain relieving persistent period two groups compares has significant difference (P < 0.05), specifically in table 3.
Table 3 liang group arthralgia relief onset time, detumescence onset time and pain relieving onset time compare
Note: compare with matched group
Δp < 0.05,
△ △p < 0.01
4. liang comparitive study that group major laboratories checks
Two groups are being improved ESR, to the negative conversion rate aspect no difference of science of statistics (P > 0.05) of RF, ASO.
Table 4 liang group is at ESR, RF, ASO efficacy analysis
Note: P > 0.05 compared with after treatment of control group
5. side effect and following up a case by regular visits to
More equal no difference of science of statistics ((P > 0.05)) before and after two groups of routine blood tests, routine urinalysis, liver function, renal function curing.Two groups all do not find obvious adverse reaction.To test group, effective above 10 patients carry out the further consultation after March, to investigate late result, wherein recur 2 examples, but symptom obviously alleviate than before the course for the treatment of.
Detailed description of the invention
Following embodiment all can realize effect described in above-mentioned experimental example.
Embodiment 1 granule of the present invention
[crude drug composition] Radix Clematidis 3000g Rhizoma Dioscoreae Nipponicae 4000g Fructus Chaenomelis 2000g
[method for making] Radix Clematidis, Rhizoma Dioscoreae Nipponicae, Fructus Chaenomelis decocts with water 3 times, each decocting time is followed successively by 1.5 hours, 1 hour, 1 hour, filter, filtrate and above-mentioned aqueous solution merge, being concentrated into relative density is 1.28(50 DEG C), stirring adds ethanol (making containing amount of alcohol to 60%), leave standstill 24 hours ~ 28 hours, get after supernatant reclaims ethanol and be evaporated to relative density 1.30(50 DEG C again), add 4 times of water gagings stirrings and make precipitation, leave standstill 24 hours, get supernatant and be evaporated to thick paste, add appropriate maltodextrin (Malto Dexfrin), stevioside, cold drying is pulverized, with debita spissitudo (50 DEG C) alcohol granulation, 60 ~ 80 DEG C of dryings, granulate, seal more than 12 hours, obtained finished product 3600g altogether, be distributed into 6g/ bag × 10 to wrap and get final product.
Embodiment 2 capsule of the present invention
[crude drug composition] Radix Clematidis 2400g Rhizoma Dioscoreae Nipponicae 5400g Fructus Chaenomelis 2200g
[method for making] Radix Clematidis, Rhizoma Dioscoreae Nipponicae, Fructus Chaenomelis decoct with water 2 times, and each decoction 2 hours, filters, filtrate and above-mentioned aqueous solution merge, and being concentrated into 50 DEG C of heat survey relative densities is 1.28, stirs and adds ethanol, make, containing amount of alcohol to 60%, to leave standstill 24 hours ~ 28 hours, get after supernatant reclaims ethanol and be evaporated to 50 DEG C of heat survey relative densities 1.30 again, add 3 times of water gagings stirrings and make precipitation, leave standstill 12 hours, get supernatant and be evaporated to thick paste, add customary adjuvant, conveniently technique, makes capsule.
Embodiment 3 Tablets
[crude drug composition] Radix Clematidis 3600g Rhizoma Dioscoreae Nipponicae 2600g Fructus Chaenomelis 2800g
[method for making] Radix Clematidis, Rhizoma Dioscoreae Nipponicae, Fructus Chaenomelis decocts with water 4 times, each decoction 1.5 hours, filter, filtrate and above-mentioned aqueous solution merge, being concentrated into 50 DEG C of heat survey relative densities is 1.28, stirring adds ethanol, make containing amount of alcohol to 60%, leave standstill 24 hours ~ 28 hours, get after supernatant reclaims ethanol and be evaporated to 50 DEG C of heat survey relative densities 1.30 again, add 5 times of water gagings stirrings and make precipitation, leave standstill 48 hours, get supernatant and be evaporated to thick paste, add appropriate amount of auxiliary materials, cold drying is pulverized, with debita spissitudo (50 DEG C) alcohol granulation, 60 ~ 80 DEG C of dryings, granulate, tabletting, obtain.
Embodiment 4 pill of the present invention
Get Radix Clematidis 3000g Rhizoma Dioscoreae Nipponicae 4000g Fructus Chaenomelis 2000g, add customary adjuvant, conveniently technique, make pill.
Embodiment 5 powder of the present invention
Get Radix Clematidis 3400g Rhizoma Dioscoreae Nipponicae 3600g Fructus Chaenomelis 2400g, add customary adjuvant, conveniently technique, make powder.
Claims (10)
1. treat a Chinese medicine composition for rheumatoid arthritis, it is characterized in that the crude drug of said composition consists of:
Radix Clematidis 10-20 weight portion, Rhizoma Dioscoreae Nipponicae 10-30 weight portion, Fructus Chaenomelis 10-15 weight portion.
2. Chinese medicine composition as claimed in claim 1, is characterized in that the crude drug of said composition consists of:
Radix Clematidis 15 weight portion, Rhizoma Dioscoreae Nipponicae 20 weight portion, Fructus Chaenomelis 10 weight portion.
3. Chinese medicine composition as claimed in claim 1, is characterized in that the crude drug of said composition consists of:
Radix Clematidis 12 weight portion, Rhizoma Dioscoreae Nipponicae 27 weight portion, Fructus Chaenomelis 11 weight portion.
4. Chinese medicine composition as claimed in claim 1, is characterized in that the crude drug of said composition consists of:
Radix Clematidis 18 weight portion, Rhizoma Dioscoreae Nipponicae 13 weight portion, Fructus Chaenomelis 14 weight portion.
5. Chinese medicine composition as claimed in claim 1, is characterized in that the crude drug of said composition consists of:
Radix Clematidis 17 weight portion, Rhizoma Dioscoreae Nipponicae 18 weight portion, Fructus Chaenomelis 12 weight portion.
6. any one Chinese medicine composition as described in claim 1-5, it is characterized in that getting traditional Chinese medicinal composition raw materials, add customary adjuvant, conveniently technique, makes powder, tablet, hard capsule, soft capsule, drop pill, pill, granule, soft extract with bee honey agent, slow releasing preparation, controlled release preparation, quick releasing formulation, oral liquid or ejection preparation.
7. the preparation method of any one Chinese medicine composition as described in claim 1-5, is characterized in that the method is:
Radix Clematidis, Rhizoma Dioscoreae Nipponicae, Fructus Chaenomelis adds 6 ~ 10 times amount soak by water 1 ~ 4 time, each decoction 1 ~ 2 hour, filter, the filtrate at every turn decocted is merged, being concentrated into 50 DEG C of heat survey relative densities is 1.28, stirring adds ethanol, make containing amount of alcohol to 60%, leave standstill 24 hours ~ 28 hours, get after supernatant reclaims ethanol and be evaporated to 50 DEG C of heat survey relative densities 1.30 again, add 3 ~ 5 times of water gagings stirrings and make precipitation, leave standstill 12 ~ 48 hours, get supernatant and be evaporated to thick paste, add customary adjuvant, conveniently technique, make powder, tablet, granule, hard capsule, pill.
8. the preparation method of Chinese medicine composition as claimed in claim 7, is characterized in that the method is:
Radix Clematidis, Rhizoma Dioscoreae Nipponicae, Fructus Chaenomelis adds 8 times of water gagings, decoct 3 times, each decocting time is followed successively by 1.5 hours, 1 hour, 1 hour, filter, the filtrate at every turn decocted is merged, being concentrated into 50 DEG C of heat survey relative densities is 1.28, stirring adds ethanol, make containing amount of alcohol to 60%, leave standstill 24 hours ~ 28 hours, get after supernatant reclaims ethanol and be evaporated to 50 DEG C of heat survey relative densities 1.30 again, add 4 times of water gagings stirrings and make precipitation, leave standstill 24 hours, get supernatant and be evaporated to thick paste, add customary adjuvant, conveniently technique, make powder, tablet, granule, hard capsule, pill.
9. the preparation method of Chinese medicinal composition granules as claimed in claim 8, is characterized in that the method is:
Radix Clematidis, Rhizoma Dioscoreae Nipponicae, Fructus Chaenomelis adds 8 times of water gagings, decoct 3 times, each decocting time is followed successively by 1.5 hours, 1 hour, 1 hour, filter, the filtrate at every turn decocted is merged, being concentrated into 50 DEG C of heat survey relative densities is 1.28, stirring adds ethanol, make containing amount of alcohol to 60%, leave standstill 24 hours ~ 28 hours, get after supernatant reclaims ethanol and be evaporated to 50 DEG C of heat survey relative densities 1.30 again, add 4 times of water gagings stirrings and make precipitation, leave standstill 24 hours, get supernatant and be evaporated to thick paste, consumption adds adjuvant maltodextrin routinely, stevioside, cold drying is pulverized, use 50% alcohol granulation, 60 ~ 80 DEG C of dryings, granulate, seal more than 12 hours, subpackage, obtain.
10. the application of any one Chinese medicine composition as described in claim 1-5 in the medicine of preparation treatment rheumatoid arthritis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310066048.8A CN103127358B (en) | 2013-03-01 | 2013-03-01 | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310066048.8A CN103127358B (en) | 2013-03-01 | 2013-03-01 | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103127358A CN103127358A (en) | 2013-06-05 |
| CN103127358B true CN103127358B (en) | 2015-03-25 |
Family
ID=48488228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310066048.8A Expired - Fee Related CN103127358B (en) | 2013-03-01 | 2013-03-01 | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103127358B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103751465B (en) * | 2013-12-31 | 2017-12-01 | 孙济平 | A kind of medicinal liquor of strengthening tendons and eliminating dampness |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1190594A (en) * | 1998-01-16 | 1998-08-19 | 刘学通 | External medicine for hyperosteogeny and preparation method thereof |
| CN101444584A (en) * | 2008-12-31 | 2009-06-03 | 江西本草天工科技有限责任公司 | Muscle-and-tendon nourishing and bone-strengthening pharmaceutical preparation and preparation method thereof |
| CN101530540A (en) * | 2009-04-14 | 2009-09-16 | 路正平 | Drug for curing rheumatoid arthritis |
| CN102846966A (en) * | 2011-06-29 | 2013-01-02 | 马树华 | A medicine for expelling pathogenic wind, relieving pain and resisting hyperosteogeny |
-
2013
- 2013-03-01 CN CN201310066048.8A patent/CN103127358B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1190594A (en) * | 1998-01-16 | 1998-08-19 | 刘学通 | External medicine for hyperosteogeny and preparation method thereof |
| CN101444584A (en) * | 2008-12-31 | 2009-06-03 | 江西本草天工科技有限责任公司 | Muscle-and-tendon nourishing and bone-strengthening pharmaceutical preparation and preparation method thereof |
| CN101530540A (en) * | 2009-04-14 | 2009-09-16 | 路正平 | Drug for curing rheumatoid arthritis |
| CN102846966A (en) * | 2011-06-29 | 2013-01-02 | 马树华 | A medicine for expelling pathogenic wind, relieving pain and resisting hyperosteogeny |
Non-Patent Citations (1)
| Title |
|---|
| 谢秀琼.工艺条件筛选.《中药新制剂开发与应用》.人民卫生出版社,2000,(第2版),第124-125及130页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103127358A (en) | 2013-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102488879B (en) | Medicinal composition for treating rheumatism | |
| CN102240372B (en) | Medicine for treating gouty arthritis and hyperuricemia and preparation method thereof | |
| CN102133271B (en) | Medicinal tea for curing gout | |
| CN103083443B (en) | Chinese medicinal composition for treating arthritis and preparation method thereof | |
| CN100382815C (en) | Compound composition for treating arthralgia caused by wind-dampness and preparation thereof | |
| CN101011544A (en) | Gout rapid recovery pill(capsule) and preparation technique thereof | |
| CN100333757C (en) | Compound traditional Chinese medicinal prepn. for preventing and treating uterus abnormal bleeding disease, and its prepn. method | |
| CN101099794A (en) | Medicine for treating rheumatic arthritis and rheumatoid arthritis | |
| CN101322823A (en) | Chinese medicine for dissipating cold, clearing heat, harmonizing nutrient and relieving pain and preparation thereof | |
| CN103223069A (en) | Traditional Chinese medicine composition for treating hepatitis | |
| CN102657736B (en) | Medicament composition for treating rheumatoid arthritis and preparation method of medicament composition | |
| CN101912577B (en) | Medicament for treating rheumatism and rheumatoid disease and preparation process | |
| CN103989996B (en) | It is a kind of to treat Chinese medicine composition of diabetes and preparation method thereof | |
| CN103127358B (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method | |
| CN101850063A (en) | Medicinal preparation for preventing and treating gout and preparation method | |
| CN102309705B (en) | Medicine for reducing serum uric acid, preparation method thereof and purpose thereof | |
| CN1943691B (en) | A Chinese traditional medicinal composition for treatment of osteoporosis and its preparation method | |
| CN107007702A (en) | A kind of Chinese medicine composition and its preparation for treating osteoarthropathy | |
| CN103191293B (en) | Sub-health-preventive drug composition and preparation method thereof | |
| CN105982906A (en) | Application of 20(R)-ginsenoside Rg3 in preparing medicines or health products capable of alleviating or/and treating rheumatoid diseases and medicines | |
| CN105194207A (en) | Traditional Chinese medicine composition and application thereof | |
| CN100441208C (en) | Bolus for treating rheumatic or rheumatoid arthritis and its preparation method | |
| CN102805795B (en) | Chinese medicinal composition for treating acute soft tissue injury of chest and hypochondrium and application thereof | |
| CN102579947A (en) | Chinese medicinal composition and preparation method thereof | |
| CN104435149A (en) | Traditional Chinese medicine composition containing kadsura pepper stem for treating gout |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150325 Termination date: 20200301 |